Anthony Welters

October 16, 2026

Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.

October 17, 2026

Carlyle Schedules Q3 Earnings as Shares Fall and Targets Cut. Carlyle Secured Lending has scheduled its Q3 earnings release and conference call for the quarter ended September 30, 2026. In recent trading, the company's shares fell, as reported in a market roundup. Analysts at UBS and TD Cowen lowered their price targets to $60 and $42, citing concerns such as the risk of private‑credit exposure to a growing AI financing wave that Carlyle highlighted.

October 17, 2026

Loews Stock Valuation Reviewed After 92% Five-Year Gain. Recent analysis suggests Loews stock appears reasonably valued following a 92% increase over the past five years. This long-term performance provides context for the current share price within its 52-week range. The commentary focuses on the stock's historical growth rather than immediate short-term movements.